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Abstract 
 
Brain-derived neurotrophic factor (BDNF) is a secreted growth factor critical for the 
establishment and maintenance of central nervous system (CNS) synapses. However, the precise 
mechanisms that allow BDNF signaling to regulate synapse formation are unknown. 
Interestingly, MAGUK scaffold proteins, a family of proteins critical for organizing the 
molecular architecture of the synapse, have altered gene expression in the brains of BDNF 
mutant mice. This suggests that BDNF’s in vivo regulation of MAGUK proteins may be 
important for the process of BDNF-induced synapse formation. Two MAGUKs with the most 
significantly decreased expression are membrane protein, palmitoylated 3 (MPP3) and 
postsynaptic density 95 (PSD95). PSD95 is a well-established mediator of synapse formation as 
demonstrated by PSD95’s colocalization with postsynaptic proteins, sufficiency to increase 
synapse density, and trafficking to synapses in a BDNF-dependent manner. However, little is 
known about the role of MPP3 in synapse formation. The specific objective for this research 
project was to determine if MPP3 positively regulates synapse development and to determine the 
requirement of MPP3 in BDNF-induced excitatory synapse formation. To test the role of MPP3 
in synapse formation two MPP3 expression constructs and three short-hairpin RNAs (shRNAs) 
were created and transfected in neuronal cultures. The neuronal cultures were fixed and stained 
for excitatory synaptic markers, VGlut1 and PSD95, and finally imaged using laser scanning 
confocal microscopy to highlight synapses on these neurons.  This methodology was used in 
order to determine if MPP3 1) localizes to postsynaptic areas, 2) is sufficient to increase synapse 
density, and 3) is required for BDNF-induced synapse formation. Based on our findings, MPP3 
localizes to potential postsynaptic regions and is sufficient to increase excitatory synapse 
formation.  
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Introduction 
 
BDNF Influences Synapse Formation 
 
Neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and Huntington’s disease 
impact millions of lives around the world (Farooqui, 2010). To understand the cellular 
mechanisms that cause these diseases, biologists try to establish connections between genes and 
disease progression. Brain-derived neurotrophic factor (BDNF) is a gene that is important for 
neuronal growth, maintenance, and plasticity in the brain. Interestingly, BDNF expression is 
decreased in the above mentioned neurodegenerative diseases. For example, studies of 
Alzheimer’s disease (AD) documented that BDNF mRNA expression is decreased in 
postmortem human brain tissue, and (Phillips et al., 1991; Mattson et al., 2008; Peng et al., 2009) 
Parkinson’s disease (PD) patients have decreased BDNF mRNA expression in substantia nigra 
neurons (Mogi et al., 1999; Howell et al., 2000; Mattson et al., 2008). Numerous reports also 
connect BDNF to neurodegeneration in Huntington’s disease (HD) where BDNF expression is 
reduced in both the disease afflicted brain regions of HD patients and also in genetically 
engineered Huntington mutant mice (Zuccato et al., 2000 and 2009; Mattson et al., 2009). In 
fact, gene expression profiling data suggests that molecular changes that occur in the striatum of 
BDNF conditional knockout mice are more similar to those that occur in humans HD patients 
than the molecular alterations in Huntington mutant mice themselves (Strand et al., 2007). From 
these studies, it is clear that alterations in BDNF expression are correlated with 
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neurodegeneration, however, a key unresolved issue is the precise mechanism that links reduced 
BDNF expression to disease progression.  
One way to understand the role of BDNF in the progression of these diseases is through 
studying its role during normal brain development. BDNF is a 14 kDa extracellular signaling 
molecule that binds to the tropomyosin receptor kinase B (TrkB) (Haniu et al., 1997; Cohen-
Corey et al., 2010). Activation of the TrkB receptor leads to an intracellular signaling cascade 
that regulates gene expression, and protein trafficking to the synapse (Yoshii and Constantine-
Paton, 2010). These effects on gene expression and protein localization ultimately allow BDNF 
to have a pronounced effect on general neuron development and, more specifically, on synapse 
development. For example, chronic treatment of hippocampal slice cultures with recombinant 
BDNF increases synapse number on apical dendrites of CA1 pyramidal cells and pulsed addition 
of recombinant BDNF in hippocampal neurons causes persistent synapse formation (Tyler and 
Pozzo-Miller et al., 2003; Taniguchi et al., 2006; Bamji et al., 2006). However, due to the nature 
of these studies, they do not provide insight into the precise role of endogenous BDNF in 
positively regulating synapse density.  
The synapse is the point of communication between two neurons. A typical excitatory 
synapse occurs between an axon terminal, called the presynapse, and a dendritic spine, called the 
postsynapse. The excitatory presynapse contains vesicles filled with the neurotransmitter 
glutamate that is transported into vesicles by vesicular glutamate transporter 1 (VGlut1) and 
ready for release into the synaptic cleft. Glutamate within the synaptic cleft then diffuses and 
binds to two classes of multi-subunit glutamate receptors, AMPA receptors and NMDA 
receptors that are anchored into the postsynaptic membrane by scaffolding proteins (Figure 1A). 
Glutamate bound AMPA and NMDA receptors act as cation channels and contribute to 
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postsynaptic depolarization, which completes the process of synaptic transmission (Boeckers, 
2006). In addition to glutamate receptors and scaffolding molecules, the postsynapse contains 
cell-adhesion molecules, membrane-bound receptors for signal transduction, and other scaffold 
proteins. This diverse network of postsynaptic proteins is called the postsynaptic density (PSD) 
because these proteins appear as a characteristic electron dense region when viewed with an 
electron microscope (Gardoni et al., 2009).  
To characterize the requirement of BDNF on synapse development, Dr. Jones’ laboratory 
created BDNF forebrain conditional knockout mice as a model to study endogenous BDNF’s 
function. The phenotype of these mice includes a reduction in dendritic spine density and 
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reduced dendrite complexity (Gorski et al., 2003; Baquet et al., 2004). Since each dendritic spine 
is thought to represent an excitatory synapse, these results suggest that BDNF is required for 
regulating the formation and/or stabilization of synapses. Interestingly, synapse loss is an early 
event during many neurodegenerative diseases (Bowen and Davison, 1983), which suggests that 
BDNF’s effects on synapse development may shed insight into the role that reduced BDNF 
signaling plays in disease. Collectively, the results from our lab and others strongly support a 
role for BDNF in synapse establishment and maintenance, but they do not provide a clear picture 
of all the complex gene expression changes that allow BDNF-TrkB signaling to regulate synapse 
formation. 
One way to identify gene expression changes that are relevant to BDNF’s effects on 
synapse formation is through analyzing changes in brain gene expression in BDNF knockout 
mice at a developmental stage where they have reduced synapse density. In order to accomplish 
this task, Dr. Jones lab performed a microarray analysis of over 20,000 protein coding mRNAs in 
BDNF knockout mice at postnatal day 35. Although numerous classes of genes were 
differentially expressed in these mice, there was a particularly striking decrease in expression of 
a group of scaffold proteins known as membrane-associated guanylate kinases (MAGUK) 
(Figure 1C). MAGUK proteins are potential key players in synaptic organization, as numerous 
MAGUKs are known to localize to the PSD (Elias et al., 2007). Two scaffold proteins with a 
particularly strong decrease in expression were postsynaptic density 95 (PSD95) and membrane 
protein, palmitoylated 3 (MPP3) (Strand et al., 2007) with both PSD95 and MPP3 exhibiting 
significantly decreased expression in the posterior cortex and the striatum (Figure 1B). Based on 
these microarray results and the strong connection between scaffolding molecules and synapse 
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development, I developed the general hypothesis that reduced MPP3 and PSD95 might be 
involved in BDNF-mediated synapse development.  
 
BDNF’s Influence on MAGUK Scaffold Proteins During Synapse Formation 
 
MAGUK scaffold proteins are cytosolic proteins that contain numerous well-conserved 
protein domains (Dimitratos et al., 1997). The conserved protein domains that all MAGUKs 
possess include at least one PSD95/Discs Large 1/Zona Occludens 1 (PDZ) domain, a src-
homology 3 (SH3) domain, and a c-terminal guanylate kinase (GK) domain (Funke, 2005; 
Gardoni, 2009) (Figure 1C). PDZ domains bind in trans to c-terminal consensus motifs, five to 
seven residues in length and facilitate protein-protein interactions, protein targeting and protein 
clustering (Elias et al., 2007). There are three canonical c-terminal sequence motifs that bind to 
the PDZ domains of MAGUK proteins: class I sequences contain Ser/Thr-X-Φ; class II 
sequences contain Φ-X-Φ; and class III sequences contain Asp/Glu-X-Φ residues (X=any amino 
acid, Φ=hydrophobic amino acid) (Harris et al., 2001; Feng et al., 2009; Lee et al., 2010). PSD95 
recognizes type I PDZ binding motifs, whereas MPP3 recognizes type II PDZ motifs (Kakunaga 
et al., 2004; Elias et al., 2007). In respect to synapse development, PDZ domains are critical 
binding regions for many synaptic proteins, including trans-synaptic adhesion proteins, 
neurotransmitter receptors, and other scaffold proteins important for signal transduction and 
general protein clustering at the PSD (Anderson, 1996; Funke, 2005; Gavarini et al., 2006). 
Unfortunately, the specific functions of the SH3 and catalytically inactive GK c-terminal 
domains are less well understood (Funke, 2005; Elias et al., 2007), but, nonetheless, the domains 
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described above suggest a possible functional role for MAGUK proteins in synapse 
development.  
The prototypical MAGUK scaffolding protein present at excitatory synapses is PSD95. 
PSD95 has three PDZ domains, an SH3 domain and GK domain. Additionally PSD95 undergoes 
palmitoylation, which is the posttranslational addition of palmitate, a 16-carbon fatty acid, via a 
thioester bond specific to cysteine residues (Dunphy et al., 1998; Resh, 1999; Funke et al., 2005). 
Since palmitate is a hydrophobic moiety, palmitoylated PSD95 is tethered to cellular membranes 
and this enables clustering of membrane embedded ion channels and neurotransmitter receptors 
(Topinka et al., 1998; 84; Funke et al., 2005). Membrane anchored PSD95 is an important 
synaptic organizing protein because of its interaction with both NMDA and AMPA glutamate 
receptors. PSD95’s PDZ domain directly binds to NMDA receptors and is necessary for 
trafficking of AMPA receptors to excitatory synapses (Kim and Sheng et al., 2004; Gardoni et 
al., 2009; Brenman et al., 1996; Doyle et al., 1996; Elias et al., 2007).  PSD95 is also sufficient to 
increase the number and intensity of excitatory synapses labeled with synaptophysin and the 
AMPA receptor subunit glutamate receptor subunit 1 (GluR1) as pre and postsynaptic markers 
respectively (El-Husseini et al., 2000). Interestingly, PSD95 not only increases synapse number, 
but it also increases the functionality of the AMPA receptors in these newly formed synapses, as 
evidenced by increased amplitude and frequency of AMPAR mediated miniature synaptic 
currents (El-Husseini et al., 2000). Thus, over-expression of PSD95 increases synapse number, 
size, and synaptic efficacy. Since both BDNF and PSD95 are sufficient to increase synapse 
formation and PSD95 expression is decreased in BDNF knockout mice this raises the following 
question: Are BDNF and PSD95 involved in a common synaptogenic signaling pathway?  
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Endogenous PSD-95 and TrkB colocalize as discrete puncta in vitro and in vivo (Yoshii 
and Constantine-Paton, 2007). Additionally, after treatment with BDNF the percentage of 
colocalized PSD-95/TrkB puncta increases from 10% to 25%. Transfection of PSD95-GFP and 
addition of BDNF increased PSD95-GFP puncta size and intensity by 30% compared to PSD95 
by itself (Yoshii-Constantine, 2007). By using BDNF bound to microspheres, Yoshii and 
Constantine-Paton demonstrated that the selective delivery of PSD95 to dendrites and synapses 
is facilitated by BDNF (Yoshii and Constantine, 2007, 2010). These observations, in conjunction 
with the work of El-Husseini et al, suggest that PSD95 is sufficient to increase excitatory 
synapse formation and that this process likely occurs in a BDNF dependent manner. Since 
MAGUK proteins are highly conserved and multiple MAGUK proteins are expressed in neurons, 
it is intriguing to ask whether other neuronal MAGUK scaffold proteins, particularly those that 
have not been investigated as intensely as PSD95, contribute to the process of BDNF induced 
synapse formation.  
 
The Role of MPP3 Within the Brain  
 One candidate molecule is the MAGUK p55 subfamily scaffold protein, MPP3. MPP3 
was discovered because of its close physical proximity to a prominent and widely known tumor 
suppressor gene, breast cancer 1 (BRCA1) on human chromosome 17. BLAST homology 
searching of fetal cDNA libraries revealed that MPP3 was homologous to MAGUK p55 protein 
(MPP1) and thus belongs in the same gene family (Smith et al., 1995; Lin et al., 1998). MPP3 is 
expressed in brain (Figure 2C), lung, pancreas, kidney, testes, liver, and skeletal muscle (Smith 
et al., 1995; Lin et al., 1998). The MPP3 protein consists of two L27 domains, a PDZ domain, an 
SH3 domain, and a GK domain from N- to C- terminal, respectively (Smith et al., 1995; Elias et 
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al., 2007). The L27 domain is an additional protein domain found in select MAGUKs that has 
established receptor trafficking capabilities (Elias et al., 2007). Due to MPP3’s conserved protein 
domains, which have well-characterized roles in synapse development, and its high expression 
within the brain, other groups have begun teasing apart MPP3’s role in neuronal development.  
Within the realm of human brain disorders, it has been documented that MPP3’s brain 
expression is altered by psychoactive medications and in patients with adverse psychological 
symptoms. In a study designed to test the effects of methylphenidate (MPH), brand name of 
Ritalin (the drug used to treat individuals with ADHD), on neuronal gene expression, Adriani 
and colleagues documented that MPH increased MPP3 mRNA expression in the striatum 
(Adriani et al., 2006). MPH has been speculated to regulate synapse plasticity in the brain, 
suggesting that MPP3 might also be involved in MPH dependent synaptic plasticity. Using gene 
expression profiling, another study documented decreased MPP3 mRNA expression in patients 
with high hallucination psychosis (Kurian et al., 2009). Collectively, these results may suggest 
that MPP3 plays  a role in modulating synaptic plasticity during the progression of human 
neurological disorders. 
Another established role for MPP3 within the brain is its direct interaction with serotonin 
receptors, 5-hydroxytryptamine type 2A (5HT2A) and 2C (5HT2C) (Becamel et al., 2004; 
Gavarini et al., 2006). Serotonin receptors play a prominent physiological role in mood, 
behavior, endocrine secretion, pain, and sleep. The serotonin receptors are highly expressed in 
various brain regions including choroid plexus, cerebral cortex, nucleus accumbens, substantia 
nigra, and striatum (Van Oekelen et al., 2003). MPP3 directly binds to 5HT2C receptors in 
primary cortical neurons and mouse brain tissue (Becamel et al., 2004; Gavarini et al., 2006) and 
Cos7 cells co-transfected with 5HT2C and MPP3 have increased 5HT2C surface expression. 
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Interestingly, similar experiments with PSD95 co-transfection caused internalization of 5HT2C 
from the cell surface, which indicates that distinct PDZ domain containing proteins can have 
antagonizing roles on the surface expression of the same receptor. In primary cortical neurons 
MPP3 was necessary and sufficient to increase the stability and sensitization of 5HT2C 
receptors. Again MPP3’s role was the opposite of PSD95, which decreased stability and 
increased desensitization of 5HT2C (Gavarini et al., 2006). Collectively, these results 
demonstrate that MPP3 directly affects the regulation of serotonin receptor delivery to the cell 
surface within neurons. Since serotonin receptors are known to modulate aspects of synapse 
strength, these results further support the notion that MPP3 influences synaptic development by 
controlling neurotransmitter receptor trafficking.   
Although MPP3’s role in synapse development is not as well characterized as PSD95, 
seminal studies have shown the direct interaction between MPP3 and various postsynapse-
associated proteins. For example, synapse-associated protein 97 (SAP97), a prominent MAGUK 
scaffold protein that recruits AMPA receptors to synapses, binds directly to MPP3’s L27 domain 
via SAP97’s MRE domain (Sans et al., 2001; Karnak et al., 2002). Further studies demonstrated 
that SAP97 and MPP3 colocalize and form a complex at the photoreceptor synapses of the 
mammalian retina (Kantardzhiva et al., 2006). MPP3 also binds to the potassium channel 
subunit, Kir2.x, though it is not clear if this is due to a direct or indirect association (Leonoudakis 
et al., 2004). Interestingly, MPP3 directly interacts via its type II PDZ domain with Nectin-like 1 
(Necl-1/SynCAM3), Nectin-like 2 (Necl-2/SynCAM1), and recently Nectin-1α molecules 
(Fukuhara et al., 2001; Leonoudakis et al., 2004; Dudak et al., 2011). Together Necl-1, Necl-2, 
and Nectin-1α are cell adhesion molecules that are highly expressed within the brain, and Necl-2 
expressed within HEK cells promotes heterologous synapse formation with cortical neurons in 
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culture (Biederer et al., 2002; Kanakunaga et al., 2005). Therefore, MPP3 clustering of Necl-1, 
Necl-2, and/or Nectin-1α may have important consequences for trans-synaptic adhesion, a 
process thought to take place during the early stages of synapse development. Due to its 
extensive association with various postsynaptic proteins these studies highlight a potential role 
for MPP3’s participation in excitatory synapse development.   
 
Hypothesis: The Role of MPP3 in Excitatory Synapse Formation 
 
In summary, MPP3 is a candidate molecule that may positively regulate synapse 
development in a BDNF dependent manner.  MPP3 expression is reduced in human neurological 
disorders that are characterized by altered synaptic plasticity, suggesting that MPP3 might play 
an important role in regulating changes in synaptic plasticity in these disorders. Furthermore, the 
interaction between MPP3 and synaptic proteins including, 5HT2C serotonin receptor, SAP97, 
the Kir2.x potassium channel subunit, and Nectin-like molecules, may highlight a role for MPP3 
in forming protein complexes with these molecules during synapse development. Based on our 
microarray results, PSD95 and MPP3 are both likely to be BDNF regulated MAGUK proteins. 
However, unlike PSD95, MPP3 is a MAGUK protein whose role in synapse development is 
largely undefined. Therefore, MPP3 might regulate excitatory synapse formation by physically 
interacting with postsynaptic proteins in a BDNF dependent manner.  The specific objective for 
this research was to determine if MPP3 positively regulates synapse development and to 
determine the requirement of MPP3 in BDNF-induced excitatory synapse formation. 
In order to carry out this objective, I created two MPP3 expression constructs, HA-human 
MPP3 (HA-hMPP3) and HA-mouse MPP3 (HA-mMPP3) and three mouse MPP3 shRNA 
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constructs. I then used these constructs to 1) determine the extent of MPP3’s colocalization with 
the postsynaptic proteins TrkB and GluR1 2) determine if MPP3 over-expression is sufficient to 
increase excitatory synapse density and 3) determine if MPP3 is required for BDNF-dependent 
synapse formation.  
 
Synapse Quantification Methodologies 
 
Since cortical neurons form functional synapses when cultured in vitro, one way to study 
synapse development is by analyzing synapse density on primary neurons in culture. In general, 
pyramidal cortical neurons consist of a single apical dendrite, which is the thickest and most 
prominent dendrite segment, a collection of proximal basal dendrites and a single axon (Figure 
3A). In experiments designed to quantify synapse density in culture, the secondary dendrites 
branching from the apical dendrite are often imaged due to the high occurrence of excitatory 
synapses on these apical branches (Knafo et al., 2001). Additionally, quantifying the secondary 
dendrites allows for consistency when measuring synapses in these highly heterogeneous 
primary cultures. 
 Fluorescent immunocytochemistry is one standard light microscopy technique that is often 
used to visualize synapses on neurons. This technique uses antibodies directed against proteins of 
interest within a cell. Since synapses contain a defined presynaptic and postsynaptic 
compartment, it is convenient to use immunocytochemistry to localize synapses on neurons by 
labeling specific presynaptic and postsynaptic proteins. A common presynaptic marker is 
vesicular glutamate transporter type 1 (VGlut1) as this highlights glutamatergic excitatory 
synapses that contain a pool of glutamate containing vesicles (Micheva et al., 2010). Studies 
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have shown that VGlut1 is expressed mainly in axon terminals, which is the presynaptic area of 
cortical neurons (Nakamura et al, 2007). PSD95, for reasons discussed in depth above, is a 
common marker used to highlight postsynaptic densities (Gutierrez et al., 2009). Together, the 
colocalization of these two markers represents an excitatory glutamatergic synapse (Sakurai et 
al., 2010). During fluorescent immunocytochemistry,  primary antibodies specific for PSD95 and 
VGlut1 bind to their respective antigens, and secondary antibodies then bind to the primary 
antibodies. The secondary antibodies are conjugated to fluorophores that emitlight of a specific 
wavelength, allowing for the proteins to be visualized under a fluorescent microscope.  
Reducing the expression, or silencing a gene, is a useful way to gain insight into the 
function of that gene in a given organism. One way to achieve gene silencing is to target its 
mRNA using short hairpin RNAs (shRNAs). ShRNAs are exogenously expressed recombinant 
DNA molecules that can induce sequence-specific gene silencing in mammalian cells (Paddison 
et al, 2002). By using this technique one can elucidate the function of a gene by observing 
cellular phenotypes in the absence of that gene. The process of shRNA mediated gene silencing 
is not 100% effective, since not all shRNAs induce silencing with the same efficiency. 
Therefore, before shRNA’s can be used to assess the function of a gene, they must first be 
validated to determine their silencing efficiency. One way to validate shRNAs is by 
cotransfecting the shRNAs along with an epitope tagged version of the target gene. This 
approach is particularly useful if a reliable antibody directed against your specific target is not 
available. For example, an MPP3 shRNA construct designed to target mouse MPP3 can be 
cotransfected with exogenous HA-mMPP3 in HEK cells. After transfection, the HEK cell protein 
lysates can be electrophoresed via SDS-PAGE and HA-mMPP3 protein levels can be assayed via 
an HA western blot. 
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Materials and Methods 
 
Animals 
All animal procedures were conducted in accordance with US Public Health Services and 
with the approval of the University of Colorado Institutional Animal Care and Use Committee. 
Neonatal rat pups used for primary culture were obtained from pregnant female rats (Charles 
River Laboratories).   
 
Vector Plasmids and Cloning  
Human MPP3 (hMPP3) protein was subcloned from the plasmid clone 41[hMPP3] into a 
pcDNA3.1(+)[HA] epitope tagging vector with Not1/Apa1 restriction sites, yielding the 
pcDNA3.1(+)[HA-hMPP3] construct. The mouse MPP3 ORF (mMPP3) was obtained from 
Open Biosystems and was then subcloned by amplifying the open reading frame (ORF) using the 
forward primer 5’- CCCGGGCAGGCATGCCAGTACTGTCTGAAGACTCG-3’ and reverse 
primer 5’-GGGCCCTTACCTCACCCAGCTGATGGGTACCCAG-3’. The amplified PCR 
product was cut with restriction enzymes Xma1/Apa1 and ligated into pCMV[HA] yielding a 
pCMV[HA-mMPP3] construct. pCMV[HA-mMPP3] construct was cut with restriction enzyme 
Nhe1/Apa1 and ligated into pcDNA3.1(+) plasmid, yielding a pcDNA3.1(+)[HA-mMPP3] 
construct.  
In order to test MPP3’s requirement on synapse formation, three shRNAs against mouse 
MPP3 were generated using the pSicoligo computer program. The three DNA oligo sequences 
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were synthetically created by IDT Technologies, and are as follows: MPP3-1 Forward 5’- TGA 
AGAGCCTCAGTTATTTATTCAAGAGATAAATAACTGAGGCTCTTCTTTTTTC-3’ and 
MPP3-1 Reverse 5’-TCGAGAAAAAAGAAGAGCCTCAGTTATTTATCTCTTGAATAAATA 
ACTGAGGCTCTTCA-3’; MPP3-2 Forward 5’- TGAATTTGTATAGTGATTTATTCAAGAG 
ATAAATCACTATACAAATTCTTTTTTC-3’ and Reverse 5’-TCGAGAAAAAAGAATTTG 
TATAGTGATTTATCTCTTGAATAAATCACTATACAAATTCA; MPP3-3 Forward 5’-T 
GTGTTTGGTGGATGTAGAATTCAAGAGATTCTACATCCACCAAACACTTTTTTC-3’ 
and Reverse 5’-TCGAGAAAAAAGTGTTTGGTGGATGTAGAATCTCTTGAATTCTACATC 
CACCAAACACA-3’. The single stranded oligos were annealed to form double stranded DNA 
oligos and ligated into pLL3.7 GFP tagged plasmid (Jack’s Lab), yielding three shRNAs, 
pLL3.7[mMPP3-1] aka shRNA M1, pLL3.7[mMPP3-2] aka shRNA M2, and pLL3.7[mMPP3-3] 
aka shRNA M3.  
All constructs listed above were transformed in DHα5 E. coli competent cells on 
ampicillin resistant agar plates overnight at 37°C. All constructs were then miniprepped using 
Promega Wizard Endotoxin Free Miniprep Kit and analyzed for DNA concentration and purity 
using the Nanodrop (Dr. Leinwand Lab). After the concentrations were determined, all plasmids 
were diluted to 100 ng/µl for easy transfections.   
 
Antibodies 
Primary antibodies used were anti-VGlut1 (rabbit; 1:2000), anti-PSD95 (mouse; 1:500), 
anti-HA (mouse; 1:1000), anti-TrkB (rabbit; 1:500), anti-GluR1 (rabbit; 1:500). Secondary anti-
bodies were goat-anti-rabbit 555 (Invitrogen; 1:2000) and goat-anti-mouse 647 (Invitrogen; 
1:2000).  
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Transfecting and cell culture 
Human embryonic kidney (HEK) cells were used to verify that 1) the hMPP3 and 
mMPP3 were expressing, and 2) the mouse MPP3 shRNAs successfully knocked down mMPP3 
expression. HEK cells were grown in DMEM supplemented with antibiotics on 12 well plates. 
They were transfected at 60-70% confluence using Lipofectamine 2000 (Invitrogen). The total 
DNA concentration was 500 ng per well: 100 ng of HA-mMPP3 or HA-hMPP3, 100 ng shRNA 
M1/M2/M3, and 300 ng of pcDNA3.1(+) empty vector. For controls, 100 ng of HA-hMPP3 or 
HA-mMPP3 and 400 ng of pcDNA3.1(+) empty vector. 24-48 hours after transfection, the HEK 
cells were processed for western blotting (Figure 2A).  
Cos7 cells were used to demonstrate hMPP3 localization and expression within Cos7 
cells. Cos7 cells were grown in DMEM supplemented with antibiotics on 24 well plates. They 
were transfected at 60-70% confluence using Lipofectamine 2000 (Invitrogen). The total DNA 
concentration was 300 ng per well: 100 ng HA-hMPP3, 100 ng Sec-61 or IRES-Cherry or Lyn-
Cherry, and 100 ng of pcDNA3.1(+) empty vector. 24-48 hours after transfection, the Cos7 cells 
were processed for confocal microscopy (Figure 2B).  
Primary cultures of cortical neurons were prepared from neonatal rats. 24 hours prior to 
culture, 12-well plates were coated with Poly-D-Lysine (PDL) to ensure cells would adhere to 
the plates successfully. The cerebral cortex was removed from newly born rat pups, treated with 
papain, triturated to ensure isolation of single cells, and plated in serum containing media 
(400,000 cells/well). Cultures were switched to B-27 supplemented serum free media after 24 
hours and were maintained at 37°C in a humidified CO2 rich atmosphere. After 7 days in vitro 
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(DIV), neurons were transfected with 100 ng of HA-hMPP3, 250 ng of pEGFP, and 150 ng of 
pcDNA3.1(+) empty vector (total of 500 ng DNA/well of transfection) with Lipofectamine 2000 
(Invitrogen). For control experiments, neurons were transfected with 250 ng GFP alone and 250 
ng of pcDNA3.1(+) empty vector with Lipofectamine 2000 (Invitrogen). This process caused 
approximately 5% of the neurons to take up and express the constructs yielding a mixture of 
over-expressing transfected neurons and wild type (untransfected) neurons. After 10 DIV, the 
transfected HA-hMPP3 neurons were processed for confocal microscopy.  
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Western Blotting 
HEK cell lysates were prepared using RIPA buffer to lyse the cells. Protein samples were 
loaded and electrophoresed in 10% SDS-PAGE gels, and then proteins on the gel were 
transferred onto nitrocellulose membranes overnight. The next day, the membranes were blocked 
in blocking buffer (10% powdered milk in TBS-Tween) for 1 hour at room temp. Next, blots 
were incubated 1 hour with primary antibody (anti-HA, then anti-tubulin) in blocking buffer. 
Blots were washed three times with blot buffer (TBS-T) and incubated with a fluorophore-
conjugated anti-mouse antibody for 1 hour at room temperature. Immunoreactivity was detected 
with method LiCor Odyssey Infrared imaging system (Figure 2A, 6B).  
 
Immunocytochemistry  
Both Cos7 cells and primary cortical neurons were fixed in 4% paraformaldehyde (PFA) 
for 30 minutes at room temperature and subsequently washed three times with PBS. Cells were 
then permeabilized with 0.1% Triton X-100 for 5 minutes, and subsequently washed in PBS 
three more times. The fixed cultures were then incubated in blocking buffer (10% normal goat 
serum (NGS) in PBS-Tween (0.25%)) for 1 hour. Cos7 cells were incubated in anti-HA (1:1000) 
primary antibody for 2 hours. Primary cortical neurons were incubated in primary antibody for 2 
hours (anti-HA, 1:1000; anti-VGlut1, 1:2000; anti-PSD95, 1:500) in PBS. After three washes 
with PBS-T, cells were incubated with secondary antibodies, 555 goat a rabbit IgG and 647 goat 
a mouse IgG. After three additional washes, the coverslips were dipped in miliQ H20, mounted 
on 18 mm circle coverslips with Fluormount G, and left in a dark area to dry overnight.  
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Imaging 
All coverslips were imaged using a Carl Zeiss Microimaging laser scanning confocal 
microscope (LSM 510) using a 100X oil objective (NA 1.4). Before imaging, each coverslip was 
blinded to protect against acquisition and processing bias. During imaging, pyramidal neurons 
with distinct apical dendrites were identified and z-stack images (0.4 micron step size) of apical 
dendrites were acquired with identical laser settings and scan speeds for all images in a single 
experiment. Between 10-15 neurons were imaged per coverslip, and each experimental condition 
consisted of 3 coverslips. Although neurons were processed for dual PSD95 and VGlut1 
fluorescence, during image acquisition there was detection of emission bleed-through from the 
22 
555 secondary antibody into the 647 channel. For this reason and to ensure accuracy, PSD95 
puncta were omitted from analysis.  
 
Puncta and Colocalization Analysis 
To quantify the number, intensity and area of synapses, Image J digital imaging software 
was used. First, all z-stack projections were merged together to form a maximum intensity 
projection (MaxZ). In order to remove camera noise inherent to all of our samples, a despeckle 
filter was applied to all images. Next for each neuron, secondary and tertiary apical dendrites 
were traced and measured for mean, min, and max signal for each fluorescent channel (Figure 3). 
Once the mean signal intensity was acquired, each dendritic segment was straightened, the 
background signal (mean times 2) was subtracted, and the straightened, background subtracted 
segments were saved as 8-bit TIFF images. Next, individual VGlut1 maxima were converted to 
binary signals using the “Find Maxima Plugin”. Finally, the “Nucleus Counter” plugin was used 
to determine the location, size and intensity of all individual VGlut1 maxima in each segment. 
All data was placed in an excel spreadsheet and statistical analysis was performed using the 
Prism software suite.  
 
Results 
 
MPP3 constructs: HA-hMPP3 and HA-mMPP3 successfully express in HEK and Cos7 cells 
Before expression constructs were transfected in neurons, the MPP3 constructs were 
validated for by 1) DNA sequencing (data not shown), and 2) expression in non-neuronal cells, 
HEK and Cos7 cells. As demonstrated in the western blot, both HA-hMPP3 and HA-mMPP3 
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protein successfully express in HEK cells, with the same protein sizes, 66 and 75 kDa, as 
endogenous MPP3 protein (Dudak et al., 2011) (Figure 2A). Additionally, hMPP3 expresses in 
Cos7 cells and colocalizes with Sec-61 (endoplasmic reticulum), Lyn-Cherry (plasma 
membrane), and IRES-cherry (cytosol) makers (Figure 2B). Due to the lack of a suitable 
antibody, the definitive localization of endogenous MPP3 could not be analyzed. 
MPP3 colocalizes with GluR1 and TrkB 
Co-transfected HA-hMPP3 and GFP rat cortical neurons were stained for either GluR1 or 
TrkB to show the localization of hMPP3 with these established synaptic markers. Qualitatively, 
images showed a fraction of HA-hMPP3 colocalizing with GluR1 and TrkB (Figure 4). 
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MPP3 is sufficient to increase VGlut1 positive puncta density, intensity, and area 
Rat cortical neurons expressing HA-hMPP3 were stained for excitatory presynaptic 
marker, VGlut1, and excitatory postsynaptic marker, PSD95. However, as mentioned above, 
PSD95 was omitted from the image processing and, thus, VGlut1 by itself was used as a proxy 
for excitatory synapses. Each VGlut1 cluster represents an individual puncta, as shown in the 
yellow circles (Figure 5A). Therefore HA-hMPP3 transfected neurons were measured for 
VGlut1 puncta density, intensity, and size compared to control expressing neurons. Since VGlut1 
is an excitatory synaptic marker, all future references to a synapse will indicate an excitatory 
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synapse (rather than inhibitory).  
The baseline control, GFP and empty vector transfected neurons, had an average puncta 
density of 0.28 puncta/µm, average puncta intensity of 40 average fluorescent units (AFUs), and 
a percent of VGlut1 puncta area per dendritic segment of 0.4% area (n = 37; neuron). Exogenous 
HA-hMPP3 expressing neurons had an average puncta density of 0.56 puncta/µm, average 
puncta intensity of 50 AFUs, and a percent of VGlut1 puncta area per dendritic segment of 
0.74% area/µm (n = 34; neuron) (Figure 5B-5C).  
Quantification for each neuron revealed statistically significant difference in VGlut1 
puncta between HA-hMPP3 and control transfected neurons. Puncta density increased 2 fold in 
HA-hMPP3 transfected neurons compared to baseline control (p<0.001). Puncta intensity 
increased by 1.2 fold in HA-hMPP3 transfected neurons compared to baseline control (p<0.05). 
Puncta size increased 1.8 fold in HA-hMPP3 transfected neurons compare to baseline control 
(p<0.001). Collectively, HA-hMPP3 significantly increased VGlut1 positive puncta density, 
intensity, and size compared to the baseline control (Figure 5). 
 
Mouse MPP3 shRNAs do not successfully decrease mouse MPP3 expression in HEK cells 
To validate mouse MPP3 shRNAs for successful knockdown of exogenous MPP3 
expression, shRNAs (M1, M2, and M3) were cotransfected along with epitope tagged, HA-
mMPP3 version of the mouse MPP3 gene. Results indicate that neither shRNAs MPP3-1, MPP3-
2, or MPP3-3 successfully decreased HA-mMPP3 expression compared to cotransfected 
Luciferase shRNA and HA-mMPP3 treated neurons (Figure 6B).  
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Discussion 
 
Synapse formation is a fundamental aspect of brain development and BDNF is a 
signaling molecule that is required for synapse formation (Baquet et al., 2004; Taniguchi et al., 
2006). However, the precise mechanisms that allow BDNF signaling to regulate synapse 
formation are unknown. Microarray analysis from BDNF knockout mice determined that the 
MAGUK scaffold proteins, a family of proteins critical for organizing the molecular architecture 
of the synapse, had altered gene expression (Strand et al., 2007). This suggests that BDNF’s 
regulation of the MAGUK family may be important for the process of BDNF-induced synapse 
formation. The two MAGUK proteins with the most significantly decreased gene expression 
were PSD95 and MPP3. PSD95 colocalizes with the postsynaptic proteins GluR1 and TrkB, is 
sufficient to increase synapse density, and is trafficked to synapses in a BDNF-dependent 
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manner (El-Husseini et al., 2000; Yoshii and Constantine-Paton, 2007). Thus, PSD95 is a well-
established mediator of synapse formation, however, relatively little is known about the role of 
MPP3 in synapse formation. Therefore, the focus of this study was to determine if MPP3 1) 
localizes to postsynaptic regions, 2) is sufficient to increase synapse density, and 3) is required 
for BDNF-induced synapse formation. 
In order to determine if MPP3 localizes to postsynaptic regions, colocalization was 
analyzed in MPP3 transfected neurons stained for the AMPA receptor subunit GluR1. Results 
demonstrated that MPP3 colocalizes with a fraction of dendritic GluR1 (Figure 4A). In previous 
studies, SAP97, whose MRE domain directly binds to MPP3’s L27 domain, directly associates 
with GluR1 subunits and scaffolds them to the postsynaptic density (Sans et al., 2001; Kim and 
Sheng, 2004; Gardoni et al., 2009; Karnak et al., 2002).). Also, PSD95 colocalizes with GluR1 
subunits and helps traffic them to the postsynaptic density (El-Husseini et al., 2000). 
Collectively, this suggests that MPP3 binding to SAP97 and scaffolding with PSD95 could 
recruit GluR1 subunits to the postsynaptic density, thus explaining the colocalization between 
MPP3 and GluR1. However, since GluR1 is not present in all AMPA receptors, and not all 
AMPA receptors are localized in postsynaptic densities (Baude et al., 1994; Martin et al., 1998), 
MPP3 colocalized with GluR1, may  not necessarily represent a postsynaptic density.  
MPP3 transfected neurons were also stained for the BDNF receptor, TrkB to highlight 
areas of MPP3 and TrkB colocalization on the dendrite. Similar to GluR1, results showed that 
MPP3 colocalizes with a fraction of dendritic TrkB receptor. Endogenous TrkB localizes to 
postsynaptic densities (Aoki et al., 2000) suggesting that MPP3 potentially localizes to TrkB 
positive postsynaptic densities. PSD95 also colocalizes with TrkB and directly associates with 
TrkB receptors in a BDNF dependent manner (Yoshii and Constantine-Paton, 2007). Together, 
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both MPP3 and PSD95 could stabilize TrkB receptors at the cell surface. If MPP3 is sufficient to 
increase the trafficking of TrkB receptors at the cell surface, than BDNF-TrkB signaling could 
increase gene expression of both MPP3 and PSD95, constituting a positive feedback mechanism. 
Since MPP3 localizes to a fraction of GluR1 and TrkB puncta and GluR1 and TrkB 
scaffolding is associated with synapse development, we next decided to investigate if MPP3 is 
sufficient to increase synaptic density. Results demonstrate that, MPP3 is sufficient to increase 
VGlut1 puncta density along transfected dendrites 2 fold compared to control neurons that were 
expressing GFP alone (Figure 5A-5B). One VGlut1 puncta along a dendrite is a proxy for an 
excitatory presynapse, and therefore, increased VGlut1 puncta density suggests an increase in the 
number of presynapses. Assuming each presynapse is adjacent to a postsynapse, an increase in 
the number of presynapses could indicate an overall increase in the number of synapses. Even 
though an increase in VGlut1 puncta occurs on the presynaptic half of the synapse, it is 
interesting to note that the postsynaptic cell transfected with MPP3 most likely mediates the 
initial effect of MPP3. Based on the above assumptions, MPP3 is sufficient to increase synapse 
density.  
Next, by using digital image analysis we determined the intensity and area of these 
VGlut1 positive synapses. MPP3 is sufficient to increase VGlut1 puncta intensity along 
transfected dendrites 1.2 fold of the intensity compared to control neurons (Figure 5C). VGlut1 
puncta intensity may suggest an increase in the number of VGlut1 molecules per synapse and, 
thus, more VGlut1 mediated glutamate transport is taking place in each terminal. Also, MPP3 is 
sufficient to increase VGlut1 puncta area 1.8 fold along the transfected dendritic segment 
compared to control neurons (Figure 5D). Increased VGlut1 area may suggest that postsynaptic 
MPP3 expression causes larger presynaptic axon terminals. Collectively, increased VGlut1 
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intensity and area may suggest that MPP3 causes more glutamate to be released per synapse and, 
thus, could potentially represent increased efficacy of these MPP3-induced synapses.  
Previously identified MPP3 interacting proteins may contribute to the process of MPP3-
induced synapse formation. Based on my results mentioned above, MPP3 is sufficient to increase 
excitatory synapse density, intensity and area. From the published literature, MPP3 directly 
interacts with synaptic proteins including SAP97, 5HT2C, Nectin-like, and Nectin (Karnak et al., 
2001; Leonoudakis et al., 2004; Kakunaga et al., 2004; Gavarini et al., 2006; Dudak et al., 2011). 
All of the proteins MPP3 directly associate with are receptors, synaptic adhesion molecules, and 
other scaffold proteins, which are important molecules in establishing and maintaining synapses 
(Figure 1B). Together, my results, demonstrating MPP3’s synaptogenic activity along with 
MPP3’s established interaction with synaptic proteins, may suggest that MPP3 recruits and 
stabilizes these synaptic proteins into newly forming synapses. It is important to note that the 
increase in VGlut1 puncta density and area occurs on the presynaptic side, but, due to the nature 
of my experiments, the postsynaptic cell transfected with MPP3 mediates the initial effect of 
MPP3.  Since MPP3 may enhance presynaptic glutamate release, these MPP3 recruited 
postsynaptic proteins may function to increase the response to glutamate. Thus, MPP3 may 
increase the overall strength as well as the number of synapses by scaffolding postsynaptic 
proteins. However, testing if MPP3 increases synaptic strength requires electrophysiology, which 
was not performed during the course of my experiments.  
The potential role for MPP3 in the process of synapse formation has been documented for 
other MAGUK proteins. For example, similar to my results with MPP3, PSD95 is sufficient to 
increase excitatory synapse density. Surprisingly, in PSD95 knockout mice, synapse morphology 
and density is unaffected, suggesting that the participation of MAGUK proteins in synapse 
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formation is a highly redundant process (Migaud et al., 1998; El-Husseini et al., 2000). One 
MAGUK molecule that could be participating in this redundant pathway may be MPP3. 
Redundancy in molecules sufficient to induce synapse formation is evolutionarily advantageous 
because synapse formation is a fundamental requirement for normal neuronal development 
(Richards et al., 2011; Bano et al., 2011). This is illustrated in the context of neurodegenerative 
diseases in which synapse loss precedes neuronal loss during degeneration, suggesting synapse 
formation is required for normal neuronal survival.  
My results demonstrate that MPP3 is sufficient to increase synapse density, but, due to 
the nature of exogenous expression experiments, my results do not indicate whether MPP3 is 
necessary to increase synapse density. The phenotype of a cell expressing exogenous MPP3 does 
not indicate the actual function of the endogenous molecule. If MPP3’s true biological function 
is to increase synapse formation, then an MPP3 loss of function experiment should demonstrate 
the opposite effect, which would suggest that MPP3 is required for synapse formation. However, 
considering the lack of a synapse phenotype in the PSD95 knockout mouse, it is possible that 
determining the absolute function of MPP3 within the overall process of synapse formation may 
be difficult. 
Although, MPP3 is sufficient to increase excitatory synapse formation, the upstream 
events that direct MPP3 to induce synapse formation are still unknown. Both BDNF and MPP3, 
individually, are sufficient to increase synapse density and based on the microarray results, we 
believe that BDNF regulates MPP3 expression. Therefore, BDNF’s positive regulation of MPP3 
may constitute a synapse formation pathway. In order to test this hypothesis endogenous MPP3 
must be knocked down using mouse MPP3 shRNAs in a BDNF gain of function background. 
Preliminary MPP3 shRNAs  did not successfully knockdown endogenous MPP3 (Figure 6). 
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However, if MPP3 is required for BDNF-induced synapse formation, then a successful 
knockdown of endogenous MPP3 expression should decrease synapse density even in a BDNF 
gain of function background.  
Though these preliminary results demonstrate a putative role for MPP3 in synapse 
formation, further research and repetition of the results is necessary. In the MPP3 colocalization 
experiments, the extent that MPP3 colocalizes with GluR1 and TrkB is not known, thus, 
quantification is necessary to show the percentage and statistical significance of colocalization. 
Furthermore, since MPP3 binds to other receptors directly (5HT2C), MPP3 could also directly 
associate with GluR1 and/or TrkB receptors. Co-immunoprecipitation assays would demonstrate 
a direct interaction between MPP3 and GluR1 and/or MPP3 and TrkB. In the MPP3 sufficiency 
for synapse formation experiment, repetition is necessary using both VGlut1 (excitatory 
presynaptic) and PSD95 (excitatory postsynaptic) markers to more accurately represent an 
excitatory synapse, however, it is recognized that the best way to characterize synapse formation 
is through electron microscopy and not immunocytochemistry. Additionally, measuring the 
AMPA receptor mediated miniature synapse currents could provide confirmation that MPP3 is 
functionally increasing the efficacy of these synapses. Lastly, the next step in this research 
project is to investigate if MPP3 is required for BDNF-induced synapse formation, which would 
provide insight into the upstream signaling molecule that mediates MPP3’s synaptogenic 
function. This future experiment would be carried out by knocking down endogenous MPP3 
expression, then adding recombinant BDNF to measure the change in synapse density.  
MPP3 is a potential excitatory synaptogenic protein. This conclusion is derived from the 
colocalization between MPP3 and synaptic markers GluR1 and TrkB, suggesting MPP3 is 
localizing to areas where there is a high concentration of these proteins and that most likely 
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represent a postsynaptic area. MPP3 is sufficient to increase VGlut1 puncta density, intensity, 
and area, which may suggest that MPP3 is a synaptogenic molecule that potentially increases the 
strength of these newly formed synapses. The potential role for MPP3 in synaptogenesis has 
never previously been established in the literature, thus my research potentially demonstrates a 
novel role for MPP3 within synapse development. To further understand what directs MPP3 to 
induce synapse formation pathway would be to investigate BDNF’s role in positively regulating 
MPP3. In conclusion, investigating the molecular constituents, such as MPP3, of a BDNF-
dependent synapse formation pathway is fundamental for our understanding of overall neuronal 
development. Neurodegeneration is characterized early on by loss of synapses, suggesting 
synapse loss could lead to neuronal loss, thus understanding the BDNF-induced synapse 
formation pathway may also provide insight into novel treatments for neurodegeneration in 
diseases that affect millions of individuals.  
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